Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases
Objective:To study EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, ras expression and ploidy in borderline tumors of the ovary by assessing their frequency, and relationship to histologic type, tumor recurrence and survival. Methods:Fifty‐four patients with borderline tumors were followed 3...
Gespeichert in:
| Veröffentlicht in: | The journal of obstetrics and gynaecology research 1998-12, Vol.24 (6), p.437-445 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 445 |
|---|---|
| container_issue | 6 |
| container_start_page | 437 |
| container_title | The journal of obstetrics and gynaecology research |
| container_volume | 24 |
| creator | Kuhn, Walther Marx, Dagmar Meidel, Andre Fattahi-Meibodi, Arjang Korabiowska, Monika Ruschenburg, Ilka Droese, Manfred Schauer, Alfred Meden, Harald |
| description | Objective:To study EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, ras expression and ploidy in borderline tumors of the ovary by assessing their frequency, and relationship to histologic type, tumor recurrence and survival.
Methods:Fifty‐four patients with borderline tumors were followed 3–140 months (median: 38 months). Paraffin‐embedded sections were stained using monoclonal antibodies against EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras. The immunohistochemical findings were correlated to histologic subtype, tumor recurrence, and survival.
Results:Positivity for EGF‐R was found in 24% (13/54), in 22% (12/54) p185 was positive, 9% (5/54) of tumors were p53‐positive, Mib‐1 (Ki‐67)‐positivity was demonstrable in 46% (25/54). Expression of Bax, Bcl‐2, and ras was found in 37% (20/54), 28% (15/54) and in 7% (4/54) of the cases, respectively.
Conclusion:The data demonstrate expression of EGF‐R, p185/HER‐2/neu, p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras in a subgroup of patients with ovarian borderline tumors. Further studies to evaluate their prognostic value are warranted. |
| doi_str_mv | 10.1111/j.1447-0756.1998.tb00121.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69176093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69176093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3527-4285712928f1071866618842b10d6fd9ade644adc581aee201484a0367eb1f9d3</originalsourceid><addsrcrecordid>eNqVkE1v1DAQhi1ERT_gLyCLA7cET-zYTg9IbaBL0YototAbljd22GyTdWsn7e6_r6Osql7xZSzNO89oHoQ-AEkhvk_rFBgTCRE5T6EoZNovCYEM0u0rdPTceh3_lEEiieCH6DiEdQyJAuQbdAiEcJoxcoT-njtvrG-bjcXXQ-d8wK7G_crixYP2u1N8hsvYbCqXXOl-5Vr3r6mw3hh82XXDxq2a0LtqZbum0i3-1Q9mNwJyhksdbHiLDmrdBvtuX0_Q74uv1-W3ZL6YXZZn86SieSYSlslcQFZksgYiQHLOQUqWLYEYXptCG8sZ06bKJWhrMwJMMk0oF3YJdWHoCfo4ce-8ux9s6FXXhMq2rd5YNwTFCxCcFDQGT6dg5V0I3tbqzjddvFQBUaNdtVajQjUqVKNdtbertnH4_X7LsOyseTE66YyBz1PgsWnt7j_Q6vtixqiIgGQCRK12-wzQ_lZxQUWubn7M1PzLz_kfcnWjSvoEC0uX7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69176093</pqid></control><display><type>article</type><title>Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kuhn, Walther ; Marx, Dagmar ; Meidel, Andre ; Fattahi-Meibodi, Arjang ; Korabiowska, Monika ; Ruschenburg, Ilka ; Droese, Manfred ; Schauer, Alfred ; Meden, Harald</creator><creatorcontrib>Kuhn, Walther ; Marx, Dagmar ; Meidel, Andre ; Fattahi-Meibodi, Arjang ; Korabiowska, Monika ; Ruschenburg, Ilka ; Droese, Manfred ; Schauer, Alfred ; Meden, Harald</creatorcontrib><description>Objective:To study EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, ras expression and ploidy in borderline tumors of the ovary by assessing their frequency, and relationship to histologic type, tumor recurrence and survival.
Methods:Fifty‐four patients with borderline tumors were followed 3–140 months (median: 38 months). Paraffin‐embedded sections were stained using monoclonal antibodies against EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras. The immunohistochemical findings were correlated to histologic subtype, tumor recurrence, and survival.
Results:Positivity for EGF‐R was found in 24% (13/54), in 22% (12/54) p185 was positive, 9% (5/54) of tumors were p53‐positive, Mib‐1 (Ki‐67)‐positivity was demonstrable in 46% (25/54). Expression of Bax, Bcl‐2, and ras was found in 37% (20/54), 28% (15/54) and in 7% (4/54) of the cases, respectively.
Conclusion:The data demonstrate expression of EGF‐R, p185/HER‐2/neu, p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras in a subgroup of patients with ovarian borderline tumors. Further studies to evaluate their prognostic value are warranted.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/j.1447-0756.1998.tb00121.x</identifier><identifier>PMID: 10063240</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; CA-125 Antigen - blood ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; ovarian borderline tumors ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; prognostic factors ; Proto-Oncogenes</subject><ispartof>The journal of obstetrics and gynaecology research, 1998-12, Vol.24 (6), p.437-445</ispartof><rights>1998 Japanese Society of Obstetrics and Gynaecology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3527-4285712928f1071866618842b10d6fd9ade644adc581aee201484a0367eb1f9d3</citedby><cites>FETCH-LOGICAL-c3527-4285712928f1071866618842b10d6fd9ade644adc581aee201484a0367eb1f9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1447-0756.1998.tb00121.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1447-0756.1998.tb00121.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10063240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuhn, Walther</creatorcontrib><creatorcontrib>Marx, Dagmar</creatorcontrib><creatorcontrib>Meidel, Andre</creatorcontrib><creatorcontrib>Fattahi-Meibodi, Arjang</creatorcontrib><creatorcontrib>Korabiowska, Monika</creatorcontrib><creatorcontrib>Ruschenburg, Ilka</creatorcontrib><creatorcontrib>Droese, Manfred</creatorcontrib><creatorcontrib>Schauer, Alfred</creatorcontrib><creatorcontrib>Meden, Harald</creatorcontrib><title>Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Objective:To study EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, ras expression and ploidy in borderline tumors of the ovary by assessing their frequency, and relationship to histologic type, tumor recurrence and survival.
Methods:Fifty‐four patients with borderline tumors were followed 3–140 months (median: 38 months). Paraffin‐embedded sections were stained using monoclonal antibodies against EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras. The immunohistochemical findings were correlated to histologic subtype, tumor recurrence, and survival.
Results:Positivity for EGF‐R was found in 24% (13/54), in 22% (12/54) p185 was positive, 9% (5/54) of tumors were p53‐positive, Mib‐1 (Ki‐67)‐positivity was demonstrable in 46% (25/54). Expression of Bax, Bcl‐2, and ras was found in 37% (20/54), 28% (15/54) and in 7% (4/54) of the cases, respectively.
Conclusion:The data demonstrate expression of EGF‐R, p185/HER‐2/neu, p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras in a subgroup of patients with ovarian borderline tumors. Further studies to evaluate their prognostic value are warranted.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal</subject><subject>CA-125 Antigen - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Middle Aged</subject><subject>ovarian borderline tumors</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>prognostic factors</subject><subject>Proto-Oncogenes</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE1v1DAQhi1ERT_gLyCLA7cET-zYTg9IbaBL0YototAbljd22GyTdWsn7e6_r6Osql7xZSzNO89oHoQ-AEkhvk_rFBgTCRE5T6EoZNovCYEM0u0rdPTceh3_lEEiieCH6DiEdQyJAuQbdAiEcJoxcoT-njtvrG-bjcXXQ-d8wK7G_crixYP2u1N8hsvYbCqXXOl-5Vr3r6mw3hh82XXDxq2a0LtqZbum0i3-1Q9mNwJyhksdbHiLDmrdBvtuX0_Q74uv1-W3ZL6YXZZn86SieSYSlslcQFZksgYiQHLOQUqWLYEYXptCG8sZ06bKJWhrMwJMMk0oF3YJdWHoCfo4ce-8ux9s6FXXhMq2rd5YNwTFCxCcFDQGT6dg5V0I3tbqzjddvFQBUaNdtVajQjUqVKNdtbertnH4_X7LsOyseTE66YyBz1PgsWnt7j_Q6vtixqiIgGQCRK12-wzQ_lZxQUWubn7M1PzLz_kfcnWjSvoEC0uX7Q</recordid><startdate>199812</startdate><enddate>199812</enddate><creator>Kuhn, Walther</creator><creator>Marx, Dagmar</creator><creator>Meidel, Andre</creator><creator>Fattahi-Meibodi, Arjang</creator><creator>Korabiowska, Monika</creator><creator>Ruschenburg, Ilka</creator><creator>Droese, Manfred</creator><creator>Schauer, Alfred</creator><creator>Meden, Harald</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199812</creationdate><title>Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases</title><author>Kuhn, Walther ; Marx, Dagmar ; Meidel, Andre ; Fattahi-Meibodi, Arjang ; Korabiowska, Monika ; Ruschenburg, Ilka ; Droese, Manfred ; Schauer, Alfred ; Meden, Harald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3527-4285712928f1071866618842b10d6fd9ade644adc581aee201484a0367eb1f9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal</topic><topic>CA-125 Antigen - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Middle Aged</topic><topic>ovarian borderline tumors</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>prognostic factors</topic><topic>Proto-Oncogenes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuhn, Walther</creatorcontrib><creatorcontrib>Marx, Dagmar</creatorcontrib><creatorcontrib>Meidel, Andre</creatorcontrib><creatorcontrib>Fattahi-Meibodi, Arjang</creatorcontrib><creatorcontrib>Korabiowska, Monika</creatorcontrib><creatorcontrib>Ruschenburg, Ilka</creatorcontrib><creatorcontrib>Droese, Manfred</creatorcontrib><creatorcontrib>Schauer, Alfred</creatorcontrib><creatorcontrib>Meden, Harald</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuhn, Walther</au><au>Marx, Dagmar</au><au>Meidel, Andre</au><au>Fattahi-Meibodi, Arjang</au><au>Korabiowska, Monika</au><au>Ruschenburg, Ilka</au><au>Droese, Manfred</au><au>Schauer, Alfred</au><au>Meden, Harald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>1998-12</date><risdate>1998</risdate><volume>24</volume><issue>6</issue><spage>437</spage><epage>445</epage><pages>437-445</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Objective:To study EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, ras expression and ploidy in borderline tumors of the ovary by assessing their frequency, and relationship to histologic type, tumor recurrence and survival.
Methods:Fifty‐four patients with borderline tumors were followed 3–140 months (median: 38 months). Paraffin‐embedded sections were stained using monoclonal antibodies against EGF‐R, HER‐2/neu (p185), p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras. The immunohistochemical findings were correlated to histologic subtype, tumor recurrence, and survival.
Results:Positivity for EGF‐R was found in 24% (13/54), in 22% (12/54) p185 was positive, 9% (5/54) of tumors were p53‐positive, Mib‐1 (Ki‐67)‐positivity was demonstrable in 46% (25/54). Expression of Bax, Bcl‐2, and ras was found in 37% (20/54), 28% (15/54) and in 7% (4/54) of the cases, respectively.
Conclusion:The data demonstrate expression of EGF‐R, p185/HER‐2/neu, p53, Mib‐1 (Ki‐67), Bax, Bcl‐2, and ras in a subgroup of patients with ovarian borderline tumors. Further studies to evaluate their prognostic value are warranted.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10063240</pmid><doi>10.1111/j.1447-0756.1998.tb00121.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-8076 |
| ispartof | The journal of obstetrics and gynaecology research, 1998-12, Vol.24 (6), p.437-445 |
| issn | 1341-8076 1447-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69176093 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal CA-125 Antigen - blood Female Humans Immunohistochemistry Middle Aged ovarian borderline tumors Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology prognostic factors Proto-Oncogenes |
| title | Borderline Tumors of the Ovary: A Clinico-Pathologic and Immunohistochemical Study of 54 Cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A46%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Borderline%20Tumors%20of%20the%20Ovary:%20A%20Clinico-Pathologic%20and%20Immunohistochemical%20Study%20of%2054%20Cases&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Kuhn,%20Walther&rft.date=1998-12&rft.volume=24&rft.issue=6&rft.spage=437&rft.epage=445&rft.pages=437-445&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/j.1447-0756.1998.tb00121.x&rft_dat=%3Cproquest_cross%3E69176093%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69176093&rft_id=info:pmid/10063240&rfr_iscdi=true |